Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Guardant Health

Biotech & Life Sciences · Palo Alto, United States · Founded 2012 · IPO 2018 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$12B
Market cap · May/2026
Revenue
$981M
Latest reported FY

Improving patient health through technology breakthroughs in oncology.

Investors

20 investors on Guardant Health's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Osage University Partners
frank malek
Sequoia
Farzad (Zod) Nazem

Global footprint

Where Guardant Health has talent and traffic

AI talent share
0.4% of workforce is AI talent
(18 of 4,475 staff)
Core AI60.13%
Other AI120.27%
Non-AI workforce4,45799.6%
Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown
Web traffic by country
85K monthly visits
across markets
🇺🇸 United States65.3%
🇬🇧 United Kingdom12.4%
🇨🇦 Canada2.9%
🇮🇳 India2.8%
🇸🇬 Singapore2.6%
Top 5 markets shown

Patent intelligence

$97M patent portfolio · 163 active families

Estimated portfolio value
$97M
0.81% of market cap · 28.1× smaller than top peer Illumina ($2.7B)
163 active patent families
Where Guardant Health innovates BioinformaticsCellComputational biologyMolecular biologyMethylation

Where Guardant Health concentrates vs peers

Each axis is a top-10 topic across Guardant Health and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Guardant Health's 2 investments and acquisitions.

Every disclosed deal where Guardant Health appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Guardant Health's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Guardant Health deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Guardant Health's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Sentiment on X

        What X is saying about Guardant Health

        An AI-synthesized read of the highest-engagement posts about Guardant Health on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Guardant Health on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.